Drugs / GSK1614235
last change Mar 2015 re-read 2 minutes ago

GSK1614235

Developed for
type 2 diabetes mellitus
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00976261 Oct 2009 → Sep 2010 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01607385 Comparator May → Dec 2012 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as GSK-1614235 GSK-1614235 and KGA-2727 are potent, selective inhibitors of the SGLT1 sodium-dependent glucose transporter.” PMID 25767259 Mar 2015
2

NCT00976261

NCT01607385

Known as DSP-3235 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965
Known as DSP-3235 SEBACATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965
Known as GSK-16142353 SEBACATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965
Known as GSK-1614235B ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965
Known as KGA-3235 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965
Known as KGA-3235 SEBACATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965
Known as KWA-0711 SEBACATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965
Known as Mizagliflozin sebacate ChEMBL registry synonym — accepted as the source's own label CHEMBL4297965
Action Inhibit “GSK-1614235 and KGA-2727 are potent, selective inhibitors of the SGLT1 sodium-dependent glucose transporter.” PMID 25767259 Mar 2015